People undergoing metabolic and bariatric surgery are less likely to develop psychiatric disorders than those treated with GLP-1 RAs.

Lower risks for anxiety disorders, substance use disorders, cognitive deficits seen for those undergoing metabolic and bariatric surgery.

VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ ...

Viking Therapeutics initiates VANQUISH phase 3 obesity clinical programme with GLP-1/GIP agonist VK2735: San Diego Thursday, June 26, 2025, 10:00 Hrs [IST] Viking Therapeutics, In ...

The Weight Loss Revolution— that’s released on Wednesday provides a detailed insight into these weight management drugs and ...

Altimmune shares jumped during after-hours trading on Wednesday after the biotech firm said it would disclose top-line ...

Emotional demands at a workplace and in-person confrontations with colleagues can increase the risk of developing diabetes by ...

Polycystic Ovary Syndrome (PCOS) affects many women, leading to a variety of symptoms that can disrupt daily life. In recent ...

Innovent Biologics presents results from DREAMS-1 phase 3 study of mazdutide in Chinese adults with T2D at ADA Scientific Sessions: San Francisco Thursday, June 26, 2025, 14:00 Hr ...

Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

A new report says Nantucket's health department will soon begin testing the island's sewage for a range of hard drugs to find ...

Men typically need between 2,000 and 3,000 calories a day, according to the Dietary Guidelines for Americans. But, your minimum (and maximum) calorie intake depends on several factors, including your ...